Risk of Pneumonia in Patients with COPD Initiating Fixed Dose Inhaled Corticosteroid (ICS) / Long-Acting Bronchodilator (LABD) Formulations Containing Extrafine Beclometasone Dipropionate versus Patients Initiating LABD Without ICS
Open Access
- 1 January 2024
- journal article
- research article
- Published by Taylor & Francis in Pragmatic and Observational Research
- Vol. ume 15, 1-16
Abstract
Background: Combined ICS and long-acting bronchodilators (LABD) more effectively reduce COPD exacerbations than LABD therapy alone. Corticosteroid-related adverse effects, including pneumonia, limit ICS use. Previous data suggest this risk is lower for extrafine beclometasone (ef-BDP). We compared pneumonia risk among new users of fixed dose ICS/LABD formulations containing ef-BDP, versus patients initiating LABD without any ICS. Methods: A propensity-matched historical cohort study design used data from OPCRD. COPD patients with ≥ 1 year of continuous data who initiated LABD or ICS/LABD formulations containing ef-BDP were matched. Primary outcome was time to pneumonia event, as treated, using either sensitive (physician diagnosed) or specific (physician diagnosed and x-ray or hospital admission confirmed) definitions, with non-inferiority boundary of 15%. Results: 23,898 COPD patients were matched, who were 68± 11 years, 54.3% male and 56% current-smokers, while 43% were former-smokers. Initiation of ef-BDP/LABD was not associated with an increased risk of pneumonia versus LABD, for either a sensitive 0.89 (0.78– 1.02), P = 0.08 or a specific 0.91 (0.78– 1.05), P = 0.18 definition of pneumonia. The probability of remaining pneumonia free 1-year after ef-BDP/LABD was 98.4%, which was comparable to LABD at 97.7%, and was sustained up to 6 years of observation; non-inferiority criterion was met for both definitions. Initiation of ef-BDP/LABD was also associated with a reduced risk of developing LRTIs in the propensity matched cohort. Conclusion: Risk of pneumonia when using ICS for the management of COPD reported in several randomised controlled trials may not be relevant with ef-BDP in a diverse real-world clinical population.Keywords
This publication has 42 references indexed in Scilit:
- Inhaled corticosteroids in COPD and the risk of serious pneumoniaThorax, 2013
- Combined corticosteroid and long-acting beta2-agonist in one inhaler versus long-acting beta2-agonists for chronic obstructive pulmonary diseaseCochrane Database of Systematic Reviews, 2012
- An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational StudiesMultivariate Behavioral Research, 2011
- Aetiology of, and risk factors for, recurrent community-acquired pneumoniaClinical Microbiology and Infection, 2009
- Community-acquired pneumonia in patients with and without chronic obstructive pulmonary diseaseJournal of Infection, 2009
- Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study resultsEuropean Respiratory Journal, 2009
- Chronic obstructive pulmonary disease and hospitalizations for pneumonia in a US cohortRespiratory Medicine, 2009
- Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthmaEuropean Respiratory Journal, 2006
- Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroidsEuropean Respiratory Journal, 2002
- Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2000